NCT05407285 is a Phase 1, PHASE2 clinical trial of Cannabis 20 mg, in Cannabis, sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

Who is sponsoring NCT05407285?

NCT05407285 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

What drugs are being tested in NCT05407285?

Interventions in NCT05407285: cannabis 0 mg, placebo, Cannabis 20 mg,, Cannabis 50 mg, Cannabis 100 mg, Cannabis 200 mg.

Is NCT05407285 still recruiting?

NCT05407285 is currently completed. Last updated 22 April 2024.

Last reviewed 2024-04-22 · How we verify

NCT05407285

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users

Completed Phase 1, PHASE2 Last updated 22 April 2024

What this trial tests

Phase 1, PHASE2 trial testing cannabis 0 mg, placebo in Cannabis in 70 participants. Completed in 14 November 2023.

Timeline

22 July 2022

Primary endpoint
14 November 2023

14 November 2023

Quick facts

Lead sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	70
Start date	22 July 2022
Primary completion	14 November 2023
Estimated completion	14 November 2023
Sites	1 location across Canada

Drugs / interventions tested

cannabis 0 mg, placebo — full drug profile →
Cannabis 20 mg, — full drug profile →
Cannabis 50 mg — full drug profile →
Cannabis 100 mg — full drug profile →
Cannabis 200 mg — full drug profile →

Conditions studied

Cannabis — all drugs for Cannabis →

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

Adults 21 to 65, any sex, with Cannabis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of this study are 1) to determine if the administration of different low doses of oral CBD (20 mg, 50 mg, 100 mg and 200 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively explore whether low dose of oral CBD is associated with effects that are not detected with the available research tools.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Sex-specific association between low oral doses of cannabidiol (CBD) and plasma concentration of anandamide (AEA), N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) in healthy occasional cannabis users.
Abboud A, Chester LA, Hébert FO, Jutras-Aswad D. · · 2026 · PMID 41514385 · DOI 10.1186/s42238-025-00356-x

Verify or expand the search:

Other recruiting trials for Cannabis

Currently open trials in the same condition.

NCT05999383 — Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration · Phase 2 · recruiting
NCT07417059 — Sex Hormones Impact on Cannabis Response · NA · recruiting
NCT07194018 — Use of Cannabis Oil in Fibromyalgia · active not recruiting
NCT06099379 — Modulation of THC Effects by CBD: a Dose-ranging Study · Phase 1, PHASE2 · recruiting
NCT05742724 — The Pharmacokinetics of Single Dose Oral Tetrahydrocannabinol and Cannabidiol · Phase 1 · active not recruiting

Other Centre hospitalier de l'Université de Montréal (CHUM) trials

Trials by the same sponsor.

NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05407285 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
Last refreshed: 22 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05407285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing